Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics or targeted oral therapies as needed. The U.S. market for conventional DMARD-refractory patients is increasingly crowded with multiple efficacious therapies, including six tumor necrosis factor-alpha (TNF-α) inhibitors, the interleukin (IL)-17 inhibitor Cosentyx (Novartis), the IL-12/23 inhibitor Stelara (Janssen), and the first-approved oral targeted PsA therapy, Otezla (Amgen). In addition, the FDA approvals of Xeljanz (Pfizer), an additional oral, first-in-class Janus kinase (JAK) inhibitor, and Taltz (Eli Lilly), a second-in-class IL-17 inhibitor, have expanded physicians’ treatment armamentarium for PsA and further increased the competition.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The Treatment Algorithms dashboard supplements our claims data analysis report and retains the full set of analyses included in the PowerPoint-based report. The interactive dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.